Life Sciences Archive » March, 2017

Life Sciences - March, 2017

373 articles

• Kimberly-Clark Gowns Failed Quality Tests, Jury Told
• Key Patents Wiped Out For Acorda's Flagship MS Drug
• A Law Firm's Guide To Social Media
• Tyco, Mutual Settle Long-Running Restoril Patent Suit
• Hedge Fund Drug Patent Challenges In Doubt After Bass' Test
• Dicerna Selling $70M In Preferred Stock To PE Group
• Health, Pharma Sectors Will Be FTC Focus, Ohlhausen Says
• Ex-Philly US Atty Predicts No Falloff In FCA Enforcement
• A Sign Of Targeted Patent Reform In Congress?
• Kimberly-Clark Exec Defends 'Quality Issues' In Fraud Trial
• Online Casanova Agrees To Pay $1.8M SEC Penalty
• Pharma Cos. Made $1B Off Wasted Cancer Drug, Suit Says
• FedEx, Merck, Quest Hit With Patent Suits Over QR Codes
• IP Licensing Co. Must Pay Medtronic's Fees In Stryker Case
• Witness's Medical Aid To Juror Spurs Pa. Risperdal Mistrial
• GSK Asks 3rd Circ. To Ignore Prior Ruling In Wellbutrin Case
• Valid Claim Buoys $131M Hearing Aid IP Verdict, Court Told
• Device Maker Wins Toss Of Investors' Illegal Kickback Claims
• Ohio Surgery Center Escapes Patients' FCA Suit
• Boehringer Ruling Limits Treatment Method Patent Eligibility
• The Future Of Off-Label Promotion And Product Liability
• Kimberly-Clark's Cost-Cutting Caused Gown Issues, Jury Told
• FDA Rejects Mylan's Application For Generic Advair
• Gov't Can't Duck Medicare Contract Cancellation Suits
• FTC May Turn Away From Court For Complex Conduct Suits
• Feds Win Extra Event Docs In Novartis Kickbacks Suit
• FTC Tells DC Circ. To Undo Boehringer Doc Privilege Ruling
• GenVec Shareholders Sue Over Intrexon Merger
• Rosen Law Firm Evades Sanctions For Quick Cellceutix Suit
• Delrahim: The Right Captain For The Antitrust Division
• Monsanto Denied Pause Of Doc Handover In Syngenta MDL
• PE Firms Collect $1.2B In Sale Of ConvaTec Shares
• Allergan Gets Patent Claims In Botox Suit Nixed At PTAB
• 'Frontier' Issues: Pay-For-Delay And Patent Holdup
• English High Court And Narrowing Scope Of Legal Privilege
• Pleading Civil RICO: Lessons From The Abbott Litigation
• EU Endocrine Disruptor Fights Could Lead To US Litigation
• A Startup Attorney's Tips To Advance Company Diversity
• UC, Medivation Argue Old Fights Decide Drug Royalty Row
• Novartis Gets Partial Win In Transplant-Drug Patent Dispute
• 3rd Circ. Won't Send Birth Control Mass Tort To State Court
• Clovis Investor Sues In Chancery Over Cancer Drug Trials
• Judge Frustrated At Sluggish Pace Of Atty Suicide Trial
• Trial Date Set For 2nd Meningitis Defendant
• FDA Warning Wire: Stem Cell Study, Bad OTC Promos
• Bayer Sues Apotex Over Cancer Treatment Patent
• Vitamin Maker Must Face 'Made In USA' Class Action
• Ex-Katten Atty Says Indictment In Shkreli Case Is 'Careless'
• What New Bulk Substance Rules Mean For The Drug Industry
• Pfizer, Ex-Employee Reach Agreement In Trade Secrets Row
• Rite Aid Wants Out Of FCA Suit Claiming Decadelong Scheme
• Goodwin Nabs Ex-Lando & Anastasi IP Atty For Boston Office
• Fosamax Ruling Aids Wellbutrin Case, 3rd Circ. Told
• Judge Gorsuch's Dubious Commitment To Legal Textualism
• SEC Scrutiny Of Non-GAAP Disclosures Likely To Continue
• Ex-Valeant CEO Sues Drugmaker Over Alleged Unpaid Shares
• Atty's Doc Says He Didn't Know Of Paxil's Suicide Risk
• Berkeley Team Gets European CRISPR Win After PTAB Loss
• ClearCorrect Gets PTAB To Nix Claims Of Invisalign Patent
• Ionis Subsidiary Akcea Files $100M IPO Led By Cooley
• Spurned Implant Inventor Again Beats PTAB At Fed. Circ.
• Salix To Pay $210M To Settle Stock Inflation Class Action
• Are Your In-House Lawyers Happy?
• Polsinelli Adds Ex-Foley & Lardner IP Atty As Shareholder
• FTC Gets Ex-Patent Atty Testimony Blocked In Androgel Suit
• Alcon Sues Lupin Over Itchy-Eye Solution Generic
• Trump's Proposed 2018 Budget Will Double FDA User Fees
• Justices Send Patent Laches Appeals Back To Fed. Circ.
• Stryker Loses Bid To Keep Poaching Suit Against DJO In NJ
• Sperm Bank Can't Dodge Couple's Suit Over Donor Portrayal
• Sullivan Worcester Reps SNH On $261M Property Stake Sale
• Proposed Rules Pose Challenges For Pharma Reps In Chicago
• Post-Escobar Courts Reaching Consensus On FCA Materiality
• Health Hires: Tucker Ellis, Wilkinson Walsh
• Medtronic Urges High Court To Open PTAB Up To More Review
• ABA President Balks At Rep's Call For More Lawyer Ad Regs
• Stryker Unit Fights To Keep DJO Poaching Suit In NJ
• Janssen Beats Untimely Calif. Appeal Over Risperdal Death
• 2 Express Scripts Claims Tossed In Anthem Contract Dispute
• Ex-Monsanto Lawyer Must Hand Over Docs In Syngenta MDL
• Fraud Claims Must Be Pulled After Smears In Pharma Co. Row
• Understanding Defense Strategies For 505(b)(2) Drugs
• 3 Sentenced In Fla. For $175M Health Care Fraud Scheme
• Pa. Judge Tosses Actiq Off-Label Marketing Suit
• TC Heartland May Cause Protective Suits In ANDA Cases
• Google, NASA, Planes And A Stronger Legal Team
• Verdict Form Reveals Close Call In Meningitis Murder Case
• Eli Lilly Case Leaves Big Questions For Another Day
• Ex-InterMune Exec Lied During SEC Trial, Judge Says
• PTAB Upholds Vimpat Patent In Generic Makers' Challenge
• CORRECTED: Diabetes Company Valeritas Prices $54M Offering
• Trial In Biomedical Stock Scheme Delayed
• Fed. Circ. OKs Rejection Of $8M Fee Bid In Gene Patent Case
• Bernstein Litowitz Gets Lead Counsel In Del. InSys Suit
• Supplement Co. Lied About Biotin Benefits, Class Action Says
• SEC Nets Insider Trading Settlement Over Merck Deal
• Generics Face Antitrust Suit Over Antidepressant Prices
• FINRA, DTC Accused Of Sending $8M To Wrong Investors
• Medical Device Giant Medtronics Sells Bonds Totaling $2B
• NuVasive Investors Win Cert. In Kickback Class Action
• Reducing Administrative Burden Under New 'Common Rule'
• Expectations For High Court Patent Exhaustion Decision
• 10 Tips For Better Legal Negotiations
• 11th Circ. Affirms $2.1M Verdict In Wright Hip Implants Suit
• 9th Circ. Buoys Policyholders In Excess Settlement Fights
• Fla. Senators Delve Into Medical Marijuana Rules Proposals
• Lilly, Biz Groups Rip Tribunal's Decision On 'Promise Doctrine'
• UK Judge Nixes Patent Extension For Merck HIV Drug
• Pharma Slams Wash. City's Suit Over Illegal OxyContin Sales
• Ex-MLBer Says Notes Show 'Sloppy' Insider Trading Probe
• Intelligender Hit With Penalty In Calif. False Ad Suit
• Drug Cos. Fight Bid For Quick Win In Namenda Antitrust Suit
• Abbott Denied Early Win In GSK Suit Over HIV Drug Cost
• Diag Human Says $325M Award Was Never Nullified
• 4 Firms Lead Canadian Biotech Aurinia's $173M Follow-On
• Breast Implants Linked To Rare Cancer, 9 Deaths, FDA Says
• Ex-Pot Dispenser Exec Pays SEC $12M Over Fraudulent Sales
• Why Patient Experience Data Provisions Face Elimination
• 3rd Circ. Revives Fosamax Warning Class Against Merck
• Damages Nixed In Generic Blood-Clot Drug Monopoly Suit
• Fund Sues For Biotech Royalty Biz Books To Aid Proxy Fight
• Jury Convicts Drug Return Co., CEO In $116M Fraud Case
• Arrowhead Investors Ask 9th Circ. To Restore Drug Trial Suit
• Plaintiffs Bar Perspective: Beasley Allen's Dee Miles
• Gray Matters: Decision Error
• Pharmacist Convicted Of Racketeering, Cleared Of Murder
• FDA Warning Wire: Data Woes For Foreign Drugmakers
• Sanofi Sues Amgen To Protect Eczema Drug From IP Claims
• FDA Expert Says GSK In Charge Of Paxil Label Changes
• AIG Unit Must Cover $3.75M Ad Injury Claims, 9th Circ. Says
• Spain Probes Pharma Giants For Restricting Competition
• PTAB Upholds Biogen Drug Patent In Hedge Fund Challenge
• Deals Rumor Mill: SoftBank, PPG, Dominion Diamond
• Levi Korsinsky Seeks Lead Role In Birth Control Investor Suit
• Law Schools And Law Firms: Seeking Common Ground
• The Rate Of PGR Petitions Hitting Orange Book Patents
• D&O Insurance And The Conduct Exclusion
• Boiron Buyers Say Jury's False Ad Verdict OK'd Sugar Pills
• Pa. Jurors Ready To Mull $116M Drug Refund Fraud Case
• Walgreens Wants Out of Theranos Blood-Testing Suit
• Trump's HHS Moving Fast To Grant Industry Wishes
• Uphold Express Scripts Quick Win Denial, Pharmacies Urge
• GSK Can't Nix Expert Testimony In Atty Suicide Trial
• Feds Indict Fugitive CEO, CFO For $426M Securities Scheme
• Meningitis Murder Trial Judge Homes In On Intent To Defraud
• FDA Probing Abbott Device's Higher Rate Of Cardiac Events
• Clovis Oncology Stock-Drop Claims Still Fall Short, Court Told
• Plaintiffs Bar Perspective: Motley Rice's Linda Singer
• Justices Reject Bid To Revive $340M Becton Antitrust Verdict
• Why We Need The Fairness In Class Action Litigation Act
• Fed. Circ. May Be Setting Stage For Big Obviousness Changes
• Regulatory Pathways Emerge For Gene-Edited Products
• Killing Class Actions Means Everybody Loses
• Not From Around Here? Trying A Case As An Out-Of-Towner
• Canada Prevails In $383M Eli Lilly Case
• Fed. Circ. Backs Dow's $5.9M Fee Award In Bayer Patent Case
• Bostwick Ch. 11 Thrown Into Crisis By Medicare Funds Freeze
• Pain Drug Co. Insys Faces Stock-Drop Suit After Audit News
• FDA Delays Off-Label Rule Opposed By Big Pharma
• Sheller Urges Justices To OK Standing In FDA Risperdal Row
• FTC, Spam Marketers Settle Charges In Fake Diet Pill Case
• Allergan Defends 3-Month Exclusivity Deal For Namenda
• Fed. Circ. Upholds Ax Of Latisse Patent Suit Against Sandoz
• FTC Can't Dodge Ruling On Litigation Authority, Watson Says
• Jury Grapples With Murder Charges In Meningitis Outbreak
• IMS Health Settles Antitrust Coverage Suit With Zurich
• 9th Circ. Affirms Amgen Win In Late Off-Label Sales Row
• German Drug Co. Stada Rejects 2 PE Takeover Offers
• Costco Shoppers Score Cert. In Supplement Labeling Suit
• Galena Lied About Illegal Fentanyl Marketing, Investor Says
• GNC, Consumers Agree To End 'Slack Fill' Suit
• 2 Noerr-Pennington Rulings Affirm Narrow Scope Of Immunity
• Trump's Hiking Of FDA User Fees Unlikely To Speed Approvals
• Another Bellwether Drops Out Of Zimmer Knee Implant MDL
• Roche, Pharmacies Reach $17M Deal Over Unwanted Faxes
• Pa. Jury Urged To Reject $116M Drug Refund Fraud Charges
• Kan. Chemist Charged With Illegally Storing Hazardous Waste
• Warner Chilcott Wins Discovery In Loestrin Pay-For-Delay MDL
• Myomo Seeks To Be 1st Reg A+ Co. To List On NYSE Venue
• 'Greed And Fraud' At Deadly Pharmacy, Murder Trial Jury Told
• Cephalon Settles FCA Suit Over Provigil Marketing
• Contract Confusion Can't Sink Drug Patent Row, Judge Says
• AstraZeneca, Zydus Reach Deal To End Nexium IP Suit
• Medtronic Investor Wants Full 8th Circ. To Rethink Case
• When The JPML Refuses To Approve Multidistrict Litigation
• What PTAB Markush Rejection Means For Biotech Applicants
• Dow Hits Teva, Actavis With Suit Over Generic Acne Med
• Allergan Investors Win Cert. In Valeant Insider Trading Row
• FDA Rejected Paxil Label Changes, GSK Says In Suicide Trial
• 2nd Xencor Class Deal Seeks $2.4M To End Recap Fight
• Ex-Oppenheimer Adviser Gets 6 Months For Insider Trading
• Greenberg Traurig Atty Brings Deep Resume To HHS Post
• FDA Panel Says Endo Painkiller Risks Exceed Benefits
• Union Hits Mylan With 2 Generic Drug Price-Fixing Suits
• There's More On USTR's Plate Than New Tariffs And NAFTA
• Puma Biotech Investors Seek Class Cert. In Stock-Drop Case
• 'Presumption Of Validity' Barred From Cialis Patent Trial
• 'Incoherent' Args Can't Defeat Roca Asset Freeze, FTC Says
• High Court Urged To Reverse Calif. Justices' Plavix Ruling
• J&J Wants Pa. Mesh Cases Paused For Jurisdiction Appeal
• Gilead Beats $50M Drug Bonus Call In Del. Chancery Ruling
• Declining Reimbursements Send Cancer Testing Co. To Ch. 11
• Blackstone Sells Life Sciences, Medical Campus For $130M
• Ex-Hunton Patent Atty Convicted Of Insider Trading
• Calif. Diabetics Denied Refund On Test Strip Sales Tax
• Biotech Co. Sued Over Stock Drop After Bad Clinical News
• A Dive Into BPCIA Confidential Info Disclosure Requirements
• FDA Faces Uncertainty Implementing 21st Century Cures Act
• Jefferies Seeks End To FINRA Arbitration Over Biotech Stock
• Medical Device Maker Seeks To Kill Weight Loss System Suit
• GSK Owes $12M To Widow of Reed Smith Atty, Jury Hears
• Mylan, Genentech Strike Deal For Herceptin Biosimilar
• Nonprofit Rips IRS' Teva Summons In Donation-Benefit Probe
• Multivitamin Has Dangerous Folate Levels, Suit Says
• Deals Rumor Mill: Walgreens, Neiman Marcus, Sealed Air
• FDA Warning Wire: Scofflaw Shuttered After 5-Year Saga
• Experts Ordered To Produce Medical Records In Benicar MDL
• 10th Circ. Affirms Suture Co. Loss In $200M Antitrust Suit
• FTC Fights Impax Bid For Fees In Pay-For-Delay Case
• Valeant Libido Drug Sales Claims Cut In Half
• Shareholder Wants Freeze On Allergan's CoolSculpting Deal
• Class Certified In 'Natural' Baby Wash Case Against J&J
• Ackman Sells Entire Valeant Stake, Takes Huge Loss
• How The Most Profitable Law Firms Structure Their C-Suites
• Veeva Countersuit Alleges IMS Monopoly Over Data Products
• Ex-Hunton Atty's Tip Not Enough To Trade On, Jury Told
• FDA Panel Weighs Safety Issues Of Endo Opioid Painkiller
• Pharma Cos. Seek To Toss Blood Pressure Drug Antitrust Suit
• Carnegie Mellon Turns To Fed. Circ. To Save Implant Patent
• W. Va. County Says Walgreens, Others Fed Opioid Epidemic
• Generic Skin Cream Buyers Fight Price-Fixing Row Dismissal
• Senate Approves Trump's CMS Administrator Pick
• Judge Skeptical Of FDA Fraud In Meningitis Murder Trial
• Sony Escapes Suit Over Dr. Oz's 'Miracle' Diet Pill Promos
• Keeping Ethics Paramount In The Direct Selling Industry
• Settlement Strategy: What Does The Client Really Want?
• Bharara Fired After Refusing To Resign
• Texas Justices Steer Clear Of Spat Among Fen-Phen Lawyers
• Amgen Warns Of 'Chaos' In High Court Biosimilar Clash
• End-Payor Actions Consolidated In Propranolol Antitrust Row
• 5 Fast Facts About Trump's Pick For FDA Chief
• PTAB Invalidates Claims In Hip Implant Patent
• Acorda MS Drug Patents Survive Kyle Bass PTAB Challenges
• Struggling Valeant Raises $3.25B In Bonds To Revamp Debt
• AbbVie Must Face Investors' Suit Over Failed $55B Merger
• Health Hires: Polsinelli, Pepper Hamilton, Mintz Levin
• Sessions Asks Obama's 46 Remaining US Attys To Resign
• 9th Circ. Says Rules Don't Call For Asbestos Suit's Eternal Nix
• Gorsuch's Views On 'Legal Tourism' Could Shift High Court
• In The Associate Lateral Market, All Law Firms Are Not Equal
• Whistleblower Protections Vs. Confidentiality Obligations
• GSK, Reed Smith Partner's Widow Preview Paxil Jury Trial
• Ex-Hunton Lawyer In Tears As Judge Refuses To Nix Charges
• Judge Gives Initial OK To Direct Digital $4.5M False Ad Deal
• Fed. Circ. Won't Look At Reach Of AIA Estoppel Provision
• 9th Circ. Urged To Recertify 'Sexual Energy' False Ad Class
• Immunomedics Transaction Halted By VenBio Challenge
• Drug, Device Makers Urge New Kickback Safe Harbors
• Reflections From A Mock Trial
• Estate Planning For The Cannabis Client
• Atty Convicted In NFLer's Stock Scheme Wins Coverage
• Perkins Coie Lures IP Partner From WilmerHale In LA
• Law Prof's Testimony Tossed In $116M Drug Return Co. Suit
• Deals Rumor Mill: Bayer, Novomatic, Stada
• Drug, Pharma Benefit Cos. Sued Over Insulin Pricing
• Prosecution Rests In Meningitis Murder Trial
• Truck Stop Asks 3rd Circ. To End $9M Drug Theft Dispute
• 6 Legal And Regulatory Risks Facing Specialty Pharmacies
• Ex-Broker Tells Of Cover-Up Over Ex-Hunton Atty's Inside Tip
• Stryker Says Biomet Poached Sales Reps, Customers, Secrets
• Durham Jones Nabs Ex-Snow Christensen IP Attys
• Drug Cos., Eye Drop Users Spar Over 7th Circ. Toss
• Pharma Co. Hit With Investor Suit Over Freeze Of Drug Study
• Deals Rumor Mill: PPG Industries, Toshiba, Novo Nordisk
• Lilly Denied Quick Win On Willful Infringement Under Halo
• Pharmacist Faked Docs After Eye Surgery Mishaps, Jury Told
• FTC Looks To Bar Ex-Patent Atty's Testimony In Androgel Suit
• Bard Stent Grafts Don't Infringe Gore Patents, Jury Finds
• NantHealth Sued After News Report Leads To Stock Drop
• Roche Wants Russian Co., Counsel Penalized For Drug Suit
• Plaintiffs Bar Perspective: Lieff Cabraser's Lexi Hazam
• District Courts And PTAB Are Divided On IPR Estoppel
• NJ Consumers Urge Court To Revive Accutane Litigation
• Ex-BigLaw Atty's Pfizer Tip Shared Among Friends, Jury Told
• Zimmer Dismissed From 137 Suits In Knee Implant MDL
• GSK Wants Paxil Study Testimony Nixed In Suicide Case
• Amgen Sues Coherus Over Chemo Drug Trade Secrets
• FDA Warning Wire: Wockhardt Again In FDA Crosshairs
• Ranbaxy Ex-Owners Must Hand Over Asset Info In Award Row
• Shining A Light On GOP Plan For Health Care Reform
• Shkreli, Ex-Katten Atty Should Not Split Trial, Feds Say
• Beyond Pay-For-Delay: 3 Pharma Antitrust Cases To Watch
• Feds, Drug Return Co. Spar Over Law Professor's Testimony
• Cannabis Industry Standards: ASTM May Fill The Vacuum
• Momenta Isn't Shielded From Antitrust Suit, 1st Circ. Says
• 7th Circ. Nixes Glaucoma Eyedropper Class Claims
• Judge OKs $12M Caldera Pelvic Mesh Deal Amid Protests
• UK Judge Nixes AbbVie Humira Patents In Biosimilars Case
• Immunomedics Directors File New Suit In Heated Proxy War
• Ex-BigLaw Partner Tells Jury He Wouldn't Break Law For $15K
• Depakote Trial Shelved Because Of Expert Witness's Illness
• Akorn Must Face Claims In VersaPharm Integration Suit
• Supplement Co. Hid SEC Subpoena, Investors Say
• PTAB Rejects IPR Challenge To Genentech Arthritis Patent
• Pharmacist Broke Down In Tears After Patient Died, Jury Hears
• PTAB Upholds Juxtapid Patents In Hedge Fund Challenge
• Pharmacy Targets Heritage, Mylan, Others Over Drug Prices
• Pa. Sen. Floats 'Right To Try' Legislation
• Direct Digital To Pay $4.5M In False Ad Settlement
• Data Analytics Now Cost-Effective For Smaller Firms
• Consumers Seek Certification In Contact Lens Antitrust MDL
• No Preemption Split To Resolve In Reglan Case, Justices Told
• Smear-And-Short Defendant Looks To Ax Default Judgment
• 'Oh, No,' Pharmacy Chief Said As Meningitis Crisis Widened
• Judge Hands Win To J&J In Latest Philly Risperdal Case
• High Court Asked To Clarify Biz Speech Antitrust Liability
• Judge Lays Out BPCIA 'Patent Dance' Rules
• J&J Gets Its First Win In Mo. Talcum Powder Trials
• GSK Won't Produce Docs In Merck Antitrust Suit, Buyers Say
• Geron, Investors Reach $6.25M Settlement In Cancer Drug Suit
• UK Accuses Actavis Of Inking Deals To Prop Up Drug Prices
• Don't Underestimate The Value Of An Internal Audit
• Fresenius Wins Bellwether Trial Over Dialysis Treatment
• Biosimilar Rules Likely To Survive ACA Battle, Lawyers Say
• In Talc Closings, J&J Invokes Dred Scott
• Goodwin Procter Partner Joins Cooley's Life Sciences Team
• Concordia Pharma Gets False Ad Trial Award Upped To $2.2M
• Mudslinging After BioZone Settlement Stumps Judge
• Celexa, Lexapro Buyers Want Class Cert. In Marketing MDL
• Cancer Treatment Center Hits Ch. 11 With $180M In Debt
• US, EU Reach Deal To Use Each Other's Drug Inspections
• Drugmaker Agrees To Stop Selling Unapproved Skin Drugs
• Challenge To FTC Authority Belongs In Calif., Agency Says
• Greenberg Sued By 'Biggest Loser' Trainer Over Contracts
• FDA Guidance On Medical Device Reporting: Key Takeaways
• Making America Manufacture Drugs Again
• Finding Jurisdiction When Paragraph IV Shifts To Paragraph III
• New Business Opportunities In Shared Workspaces
• CORRECTED: Greenberg Traurig Settles Malpractice Suit As Trial Closes
• CEO's $46M IPO Windfall Not Fraud, Cancer Therapy Co. Says
• GSK Says Reed Smith Atty's Job Anxieties Led To Suicide
• Pfizer Wins TRO In Info Theft Suit Against Ex-Marketing Head
• 20 More States Join Generic Drug-Pricing Antitrust Action
• Theranos Says Investors Can't Sue Over Blood Tests
• Doctor Asks 11th Circ. To Rehear Enbrel Libel Case
• Fed. Circ. Affirms $455M Award To Bayer In Dow Patent Case
• Biosimilar Talks Needed To Trigger Litigation Clock: Judge
• Fed. Circ. Asked To Decide When Appeals Require Opinion
• Pa. Appeals Court OKs Attys' Fees Claim Above Damage Cap
• Long-Awaited IP Trial Between WL Gore, CR Bard Kicks Off
• 8th Circ. Affirms Dismissal Of Medtronic Derivative Suit
• Bayer Aims To Trim Debt In $1.58B Covestro Stake Sale
• Pfizer Prices €4B Bond To Repay Debt
• Genentech Biosimilar Suit Tossed After Just 2 Weeks
• Former ArthroCare Exec Wants 5th Circ.'s Decision Enforced
• Calif. County Can't Take Avandia Ad Claims To State Court
• PTAB Upholds Vimovo Patent Claims Challenged By Lupin
• A Survey Of Recent Life Sciences Securities Class Actions
• 2nd Requests Almost Always Spell Trouble For Deals
• FDA Oversight Of Lab-Developed Tests Is Likely To Lessen
• 2016 Patent Litigation: A Year In Review
• Patent Litigation 2016: A Law360 Special Report
• These Law Firms Dominated At The Federal Circuit In 2016
• Patent Litigation In US District Courts: A 2016 Review
• 4 Frequent Filers Of IP Suits To Watch This Year
• The Federal Circuit Judges You Want On Your PTAB Appeal
• Fed. Circ. Taking Harder Look At PTAB Appeals
• Inter Partes Reviews Becoming Friendlier To Patent Owners
• AIA Proceedings At The Patent Board: A Closer Look
• Law360's Federal Circuit Snapshot: By The Numbers
• Fed. Circ. Issuing More 'Hidden Decisions' Amid Case Influx
• ITC Patent Cases Rebound To Reach 5-Year High
• What The Intuitive Ruling Means For Medical Device Makers